Mon, August 6, 2012
Fri, August 3, 2012
Thu, August 2, 2012
[ Thu, Aug 02nd 2012 ] - Market Wire
00 p.m. EDT
Wed, August 1, 2012
[ Wed, Aug 01st 2012 ] - Market Wire
Head of European Operations
Tue, July 31, 2012
Mon, July 30, 2012
Sun, July 29, 2012
Fri, July 27, 2012
Thu, July 26, 2012
Wed, July 25, 2012
Tue, July 24, 2012
[ Tue, Jul 24th 2012 ] - Market Wire
Neogen reports year end results
Mon, July 23, 2012
Sun, July 22, 2012
Sat, July 21, 2012
Fri, July 20, 2012
Thu, July 19, 2012
Wed, July 18, 2012
Tue, July 17, 2012
Mon, July 16, 2012
[ Mon, Jul 16th 2012 ] - Market Wire
30 a.m. ET
Fri, July 13, 2012
Thu, July 12, 2012
Wed, July 11, 2012
Tue, July 10, 2012
Mon, July 9, 2012

Savient Pharmaceuticals Receives Favorable Decision In Tang Capital Litigation


//health-fitness.news-articles.net/content/2012/ .. vorable-decision-in-tang-capital-litigation.html
Published in Health and Fitness on by Market Wire   Print publication without navigation


Savient Pharmaceuticals Receives Favorable Decision In Tang Capital Litigation -- EAST BRUNSWICK, N.J., July 23, 2012 /PRNewswire/ --

Savient Pharmaceuticals Receives Favorable Decision In Tang Capital Litigation

[ ]

Court Determines No Event Of Default Has Occurred

EAST BRUNSWICK, N.J., July 23, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: [ SVNT ]) today announced that the Delaware Court of Chancery has issued a bench ruling granting both of Savient's motions in the lawsuit brought against the Company by Tang Capital Partners, LP and certain other holders of Savient's convertible notes.  The Court of Chancery decided that the plaintiff noteholders do not have standing to bring an action to appoint a receiver for Savient and that an event of default has not occurred under Savient's convertible notes. The Court has not yet come to a conclusion on the plaintiff's claims for breach of fiduciary duty and waste.  Savient continues to believe that all outstanding claims alleged by the plaintiffs are without merit, and intends to vigorously defend this lawsuit to its completion.  The Court of Chancery's decision is subject to appeal by the plaintiffs.  In addition, Savient's claim for damages against Tang Capital remains outstanding. 

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP").  Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the Company's website at [ www.savient.com ].

Contact:                                                                                              

Mary Coleman                       

Kelly Sullivan / Taylor Ingraham 

Savient Pharmaceuticals, Inc.   

Joele Frank, Wilkinson Brimmer Katcher

[ information@savient.com ]            

[ ksullivan@joelefrank.com ] / [ tingraham@joelefrank.com ]

(732) 418-9300                             

(212) 355-4449

 

 

SOURCE Savient Pharmaceuticals, Inc.



[ Back to top ]

RELATED LINKS
[ http://www.savient.com ]


Publication Contributing Sources